Gain Therapeutics

About Gain Therapeutics

Gain Therapeutics is a biotechnology company focused on developing next-generation allosteric small molecule therapies to meet patient needs, particularly for disorders with high unmet medical needs. They combine physics-based methods with artificial intelligence to create best-in-class small molecules.

Products & Services

GT-02287:A lead drug candidate, which is a best-in-class small molecule for the treatment of GBA-Parkinson's disease and other neurodegenerative diseases, currently in a Phase I clinical study.

Magellan™ Platform:A drug discovery platform leveraging AI-supported 3D structural biology and supercomputer-powered physics-based models to identify novel allosteric binding sites on disease-implicated proteins.

Allosteric Protein Regulation Therapies:Next-generation allosteric small molecule therapeutics designed to modulate protein function through stabilization, destabilization, degradation, inhibition, or activation based on disease pathology.

Specialties

Allosteric Small Molecule Therapies Neurodegenerative Diseases GBA-Parkinson's Disease Treatment AI-Supported Drug Discovery 3D Structural Biology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 7000000 MR: - FA: $7.0 Million FAN: 7000000	D: 2025-07-16 FD: 2025-07-16	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 11000000 MR: - FA: approximately $11.0 million FAN: 11000000	D: 2024-06-13 FD: 2024-06-13	1 investors
3	RT: Underwritten Public Offering and Private Placement T: - FT: Underwritten Public Offering and Private Placement	A: 10100000 MR: - FA: 10.1 million FAN: 10100000	D: 2023-11-24 FD: 2023-11-24	3 investors
4	RT: Public Offering and Concurrent Private Placement T: - FT: Public Offering and Concurrent Private Placement	A: 9400000 MR: - FA: $9.4 million FAN: 9400000	D: 2023-11-21 FD: 2023-11-21	2 investors
5	RT: Grant T: - FT: Grant	A: 2800000 MR: - FA: CHF 2.5 million FAN: 2800000	D: 2023-05-03 FD: 2023-05-03	1 investors
6	RT: Grant T: - FT: Grant	A: 1200000 MR: - FA: €1.2 million FAN: 1200000	D: 2023-03-21 FD: 2023-03-21	2 investors

Public Offering Latest

2025-07-16

$7.0M

1 investor (Pro only)

Public Offering 2024-06-13

$11.0M

Underwritten Public Offering and Private Placement 2023-11-24

$10.1M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ram Selvaraju

Senior Healthcare Equity Research Analyst

G

Gene Mack

Chief Executive Officer

LinkedIn (Pro only)

J

Jonas Hannestad

Chief Medical Officer

LinkedIn (Pro only)

T

Terenzio Ignoni

SVP Technical Operations

J

Joanne Taylor

SVP, Research

G

Gianluca Fuggetta

Senior Vice President, Finance

View 14 more team members with Pro

Unlock Full Team Directory

Recent News